Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Depreciation & Amortization (CF): 2019-2024

Historic Depreciation & Amortization (CF) for Phathom Pharmaceuticals (PHAT) over the last 6 years, with Dec 2024 value amounting to $795,000.

  • Phathom Pharmaceuticals' Depreciation & Amortization (CF) fell 18.32% to $156,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $698,000, marking a year-over-year decrease of 11.31%. This contributed to the annual value of $795,000 for FY2024, which is 38.26% up from last year.
  • Phathom Pharmaceuticals' Depreciation & Amortization (CF) amounted to $795,000 in FY2024, which was up 38.26% from $575,000 recorded in FY2023.
  • Phathom Pharmaceuticals' 5-year Depreciation & Amortization (CF) high stood at $795,000 for FY2024, and its period low was $323,000 during FY2020.
  • Its 3-year average for Depreciation & Amortization (CF) is $663,333, with a median of $620,000 in 2022.
  • Per our database at Business Quant, Phathom Pharmaceuticals' Depreciation & Amortization (CF) spiked by 3,937.50% in 2020 and then fell by 7.26% in 2023.
  • Over the past 5 years, Phathom Pharmaceuticals' Depreciation & Amortization (CF) (Yearly) stood at $323,000 in 2020, then spiked by 61.30% to $521,000 in 2021, then climbed by 19.00% to $620,000 in 2022, then decreased by 7.26% to $575,000 in 2023, then soared by 38.26% to $795,000 in 2024.